Januvia 100mg. Sitagliptin
100mg. Buy Januvia online
What is
Januvia?
Januvia 100mg (Sitagliptin) is an oral
hypoglycemic drug which belongs to the group of medicines called
selective inhibitors of dipeptidyl peptidase-4.
Januvia
increasesthe concentration of glucagon-like peptide-1 and
glucose-dependent insulinotropic peptide in blood plasma. Thus,
increases insulin secretion, reduces glucagon secretion and
glycosylated hemoglobin levels in patients with diabetes mellitus
type II. The level of glycemia is decreased as well.
Is used to treat
non-insulin dependent diabetes mellitus (II type).
Pharmacological properties
Januvia 100mg (Sitagliptin) is an oral
hypoglycemic drug, a selective inhibitor of dipeptidyl peptidase-4.
It works by increasing the concentration of glucagon-like peptide-1
and glucose-dependent insulinotropic peptide in blood plasma. It
helps increase insulin secretion, causes reduction of glucagon
secretion, glycosylated hemoglobin levels and blood glucose levels
in patients with diabetes mellitus type II. Januvia is a highly
selective inhibitor of dipeptidyl peptidase-4 (DPP-4).
Sitagliptin is
different in structure and action mechanism from insulin,
sulfonylureas and biguanide derivatives, analogues of glucagon-like
peptide-1 agonists, PPAR-gamma (gamma receptor, peroxisome
proliferator-activated) inhibitors of alpha-glycosidase, amylin
analogues.
Inhibition of dipeptidyl peptidase-4 leads to increased
concentrations of two known incretins: glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide (GIP). These
incretins are secreted into the intestine and their concentration
is increased in response to food intake. They are part of the
internal physiological regulation of glucose homeostasis. At normal
or elevated blood glucose levels these incretins contribute to
increase of insulin synthesis and secretion of its beta-cells of
the pancreas by cAMP-associated signaling intracellular
mechanisms.
Glucagon-like peptide-1 also contributes to the suppression of
increased glucagon secretion by alpha-cells in the pancreas.
Reducing the concentration of glucagon, accompanied by increased
levels of insulin helps reduce hepatic glucose production,
resulting in a decrease of glycemia levels.
|